Health and Healthcare

Dendreon, When 200% Sales Growth Is Not Enough (DNDN)

Source: Author
Dendreon Corporation (NASDAQ: DNDN) has reported its quarterly results and the reaction is a bit cool. This is growth of almost 200%, as net product revenue for the quarter was $82.0 million versus $27.0 million a year ago. The net loss in the first quarter was $103.9 million, or -$0.70 per share, and that is down from a net loss of $112.8 million a year ago. Excluding cash and noncash severance expenses, the report would have been for a net loss of $87.1 million, or -$0.59 per share.

Thomson Reuters has estimates of -$0.63 EPS and $81.23 million in sales. The company called this report as having exceeded its guidance of low single-digit quarter-over-quarter growth.

Dendreon had approximately $559.1 million in cash, cash equivalents and short-term and long-term investments as of March 31, down from $617.7 at the end of the December 31, 2011 period.

Without formal guidance, we cannot consider this report as “finished business” until that data is out.

Dendreon shares closed up 3.2% at $11.69 against a 52-week range of $6.46 to $42.87, and shares are down 7.3% at $10.82 in the after-hours session.

JON C. OGG

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here
you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.


Click here
to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.